Here we present an audit from a large, single-centre’s severe asthma service which looks for the prevalence of RA across all patients being treated with mepolizumab and benralizumab, two commonly used anti-IL-5 therapies. The gene discussed is IL5; the disease is rheumatoid arthritis.